Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2019-04-17

Summary

The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: AbbVie
• Treatments: Carboplatin; Etoposide; Etoposide phosphate; Veliparib